A study from the University of California, La Jolla, CA, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November 2009 issue of Nature Medicine by Prof. Thistlethwaite PA, Li X and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for pulmonary arterial hypertension: Arctigenin, commonly known as greater burdock, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene. Together, pharmacological formulations encompassing “Arctigenin or its analogues“ may be used to treat pulmonary arterial hypertension.
Amount: $ 500*
Undisclosed information: How Arctigenin decreases pulmonary arterial hypertension
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Natural product-based therapy for pulmonary arterial hypertension: Arctigenin inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 3/February/2015, 23.51, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
